Do patients need to take quizartinib for life?

Quizartinib is an oral, highly effective type II inhibitor of FLT3, specifically developed to treat adult patients with FLT3-ITD-positive acute myeloid leukemia. Acute myeloid leukemia (AML) is a malignant clonal disease originating from hematopoietic stem cells. It is characterized by abnormal proliferation of blast cells in the bone marrow, which inhibits normal hematopoietic function and may infiltrate into other organs and tissues. FLT3-ITDmutation is one of the common molecular abnormalities in AML patients and is closely related to the prognosis of the disease.

There is no absolute answer as to whether patients need to take quizartinib for life. The period and duration of treatment with quizartinib generally depends on the patient's response to treatment and the progression of the disease. For some patients, quizartinib may be part of a long-term treatment regimen, meaning patients may need to take the drug for a long time to keep their disease under control. However, this does not mean that all patients need to take it for life.

In actual treatment, doctors will formulate and adjust treatment plans based on the patient's specific situation and changes in condition. If the patient responds well to treatment with Quizartinib and the disease is effectively controlled, the dose may be gradually reduced or the drug may be discontinued under the guidance of a physician. Conversely, if a patient develops resistance or the disease progresses, doctors may consider switching to other treatment options or drugs.

In addition, as a targeted therapy drug, quizartinib’s side effects and safety are also factors that need to be considered. Patients will need regular blood tests and other related tests while taking Quizartinib to monitor the drug's effects and potential side effects. Doctors will adjust the dose of medication or treatment plan based on the results of these tests.

In general, whether a patient needs to take quizartinib for life depends on a variety of factors, including the patient's specific condition, changes in condition, and the efficacy and safety of the drug. Therefore, during the treatment process, patients should closely cooperate with the doctor's treatment plan and undergo regular follow-up and monitoring. At the same time, with the continuous advancement of medical research and the continuous emergence of new drugs, more and better treatment options may appear in the future, bringing better treatment effects and quality of life to patients.

xa0

References:https://www.news-medical.net/news/20231211/Quizartinib-extends-life-and-enhances-wellbeing-for-AML-patients-with-key-mutation.aspx